COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Amendments are illustrated by showing deletions ~~by strikethrough~~ or by [[double brackets]] for deletions of five or fewer characters and additions by underlining)

Claims 1-17 (canceled)

Claim 18 (previously presented): A compound of the formula:



wherein

A^1 is a D- or L-isomer of an aromatic amino acid or is deleted;

A^3 is an aromatic amino acid;

A^6 is Thr, Thr(Bzl), Gly, Ser, an Eaa or an aliphatic amino acid;

A^8 is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid or an aliphatic amino acid;

each of R_1 and R_2, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E_1SO_2 or E_1CO wherein E_1, is aryl, aryl lower alkyl, heterocycle or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl or hydroxy lower alkyl; and

R_3 is OH, NH_2, C_{1-12} alkoxy or NH-Y-CH_2-Z, wherein Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO_2H or $CONH_2$,

provided that R_3, together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

further provided that a disulfide bond links the sidechains of A^2 and A^7; and

further provided that if A^1 is D-Phe or p-NO_2-Phe, A^3 is Phe or Tyr and A^6 is Thr or Val, then A^8 is ß-Nal.

19 (previously presented): A compound of claim 44, wherein A^1 is the D- or L-isomer of ß-Nal, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, F_5-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A^3 is ß-Nal, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, F_5-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A^6 is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, ß-Ala, Gaba, or Val; and A^8 is the D- or L-isomer of Thr, Dip, F_5-Phe, p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, Igl, Tyr(Bzl), or ß-Nal.

20 (previously presented): A compound of claim 19, wherein A^1 is the D- or L-isomer of ß-Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe; A^3 is Tyr, Tyr(I), or Pal; A^6 is Val, Tle, Nle, Ile, or Leu; A^8 is p-F-Phe, ß-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R_1 is H, CH_3CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; and R_2 is H.

21 (original): A compound of claim 20, wherein A^3 is Pal.

22 (previously presented): A compound of claim 19, of the formula:

H_2-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxymethyl)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H(CH_3CO)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(CH_3CO)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H_2-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H_2-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H_2-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H_2-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H_2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H_2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H_2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H_2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(CH_3CO)Phe-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H_2-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl)ethylamide;

H_2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl)ethylamide;

H_2-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide; or

H_2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

or a pharmaceutically acceptable salt thereof.

23 (previously presented): A compound of the formula:



wherein

A^1 is a D- or L-isomer of an aromatic amino acid, or is deleted;

A^2 is a D-aromatic amino acid,

A^3 is an aromatic amino acid;

A^6 is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid;

A^7 is an aromatic amino acid or an aliphatic amino acid;

A^8 is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R_1 and R_2, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E_1SO_2 or E_1CO wherein E_1, is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

R_3 is OH, NH_2, C_{1-12} alkoxy, or NH-Y-CH_2-Z, wherein Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO_2H, or $CONH_2$, or R_3, together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl.

24 (previously presented): A compound of claim 23, wherein A^1 is an L- amino acid and A^2 is a D-aromatic amino acid.

25 (previously presented): A compound of claim 24, wherein each of A^1, A^3, and A^7, is, independently, ß-Nal, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN or NO_2, p-X-Phe

wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN or NO_2, m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, F_5-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A^2 is D-ß-Nal, D-o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, D-p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, D-m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, D-F_5-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A^6 is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, ß-Ala, Gaba, or Val; and A^8 is the D- or L-isomer of Thr, Dip, F_5-Phe, p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, Igl, Tyr (Bzl), or ß-Nal.

26 (previously presented): A compound of claim 25, wherein A^1 is ß-Nal or Phe, A^2 is D-Cpa or D-Phe; A^3 is Phe or Tyr; A^6 is Abu, Thr, or Val; A^7 is Phe; and A^8 is Thr; R_1 is H, CH_3CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)- 1-piperizineethanesulfonyl; R_2 is H; and R_3 is NH_2.

27 (previously presented): A compound of claim 25 of the formula:

H_2-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;

H_2-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa - Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;

H_2-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH_2;

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

(H)(CH_3CO)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa - Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2;

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2; or

H_2-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2; or

a pharmaceutically acceptable salt thereof.

28 (original): A compound of claim 23, wherein A^1 is a D-amino acid and A^2 is a D-aromatic amino acid.

29 (previously presented): A compound of claim 28, wherein each of A^1 and A^2, is, independently, D-ß-Nal, D-o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, D-p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, D-m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, D-F_5-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; each of A^3 and A^7, independently, is ß-Nal, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, m-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, F_5-Phe, Trp, Dip, 2-Pal, His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or Pal; A^6 is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, ß-Ala, Gaba, or Val; and A^8 is the D- or L-isomer of Thr, Dip, F_5-Phe, p-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, o-X-Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, m-X-

Phe wherein X is H, OH, CH_3, halo, OCH_3, NH_2, CN, or NO_2, Igl, Tyr(Bzl), or ß-Nal.

30 (previously presented): A compound of claim 29, wherein A^1 is D-ß-Nal or D-Phe; A^2 is D-Cpa or D-Phe; A^3 is Phe or Tyr; A^6 is Thr or Val; A^7 is Phe; A^8 is Thr; R_1 is H, CH_3CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R_2 is H; and R_3 is NH_2.

31 (previously presented): A compound of claim 29 of the formula:

H_2-D-ß-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-D-ß-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2;

H_2-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-D-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;

H_2-D-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH_2; or

a pharmaceutically acceptable salt thereof.

32 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

33 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

34 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

35 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

36 (previously presented): A method of imaging cells having somatostatin receptors which comprises administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 18 having Tyr(I).

37 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

38 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

39 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

40 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

41 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

42 (previously presented): A method of imaging cells having somatostatin receptors which comprises administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 23 having Tyr(I).

43 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

44 (previously presented): A compound of claim 18, wherein A^8 is a D- or L-isomer of Thr or ß-Nal; and R_3, together with A^8, form (2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide or 2R-(2-naphthyl)ethylamide; or a pharmaceutically acceptable salt thereof.